News
GHRS
14.57
-1.02%
-0.15
GH Research files Form 3 for COO Cameron Aaron Luke beneficial ownership statement
Reuters · 1d ago
GH Research files Form 3; Director Dermot Hanley reports beneficial ownership
Reuters · 1d ago
GH Research files Form 3 for Ireland managing director Halle Magnus Clemensen
Reuters · 1d ago
GH Research director Michael Forer files initial beneficial ownership statement
Reuters · 1d ago
GH Research files Form 3 showing CEO Velichka Valcheva beneficial ownership
Reuters · 1d ago
GH Research files Form 3 for VP Finance Julie Ryan beneficial ownership
Reuters · 1d ago
GH Research files Form 3 as director Florian Schonharting reports beneficial ownership
Reuters · 2d ago
Weekly Report: what happened at GHRS last week (0323-0327)?
Weekly Report · 5d ago
GH Research (GHRS) Price Target Increased by 18.94% to 40.04
NASDAQ · 03/28 02:01
'Bipartisan Senators File Bill To Support Psychedelics Research And Treatment For Veterans' - Marijuana Moment
Benzinga · 03/27 17:28
Psychedelic: Compass Pathways, NRx Pharma report earnings results
TipRanks · 03/26 15:00
GH Research Publishes Phase 2b GH001 TRD Data and Highlights Severity-Independent Efficacy
TipRanks · 03/25 15:49
GH Research announces publication of Phase 2b results for mebufotenin
TipRanks · 03/25 15:15
GH Research Announces Two-Peer Reviewed Publications From Its Phase 2B Clinical Program Of GH001 For Treatment-Resistant Depression
Benzinga · 03/25 15:14
GH Research announces JAMA Psychiatry publication of Phase 2b GH001 results in treatment-resistant depression; reports efficacy independent of prior antidepressant failures
Reuters · 03/25 15:10
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
Barchart · 03/25 10:10
Weekly Report: what happened at GHRS last week (0316-0320)?
Weekly Report · 03/23 09:22
GH Research to join fireside chat at Stifel Virtual CNS Forum
Reuters · 03/16 11:38
Weekly Report: what happened at GHRS last week (0309-0313)?
Weekly Report · 03/16 09:22
GH Research: Advancing GH001 Toward 2026 Pivotal Phase 3 in Treatment-Resistant Depression With Favorable Risk-Reward and $70 Target
TipRanks · 03/12 14:35
More
Webull provides a variety of real-time GHRS stock news. You can receive the latest news about Gh Research Plc through multiple platforms. This information may help you make smarter investment decisions.
About GHRS
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.